MDRX 📈 Veradigm - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US01988P1084
MDRX: Healthcare Software, Electronic Records, Payment Solutions, Analytics Tools
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois. Web URL: https://veradigm.com
Additional Sources for MDRX Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MDRX Stock Overview
Market Cap in USD | 1,146m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 1999-07-26 |
MDRX Stock Ratings
Growth 5y | 3.70% |
Fundamental | - |
Dividend | 0.30% |
Rel. Strength Industry | -171 |
Analysts | 3.75/5 |
Fair Price Momentum | 8.62 USD |
Fair Price DCF | 16.27 USD |
MDRX Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 1.0% |
MDRX Growth Ratios
Growth Correlation 3m | 57.5% |
Growth Correlation 12m | 49.3% |
Growth Correlation 5y | -4.9% |
CAGR 5y | -0.70% |
CAGR/Mean DD 5y | -0.02 |
Sharpe Ratio 12m | -0.05 |
Alpha | -34.21 |
Beta | 0.94 |
Volatility | 43.58% |
Current Volume | 161.3k |
Average Volume 20d | 330.6k |
What is the price of MDRX stocks?
As of December 22, 2024, the stock is trading at USD 9.50 with a total of 161,337 shares traded.
Over the past week, the price has changed by -5.00%, over one month by -9.61%, over three months by -2.56% and over the past year by -3.65%.
As of December 22, 2024, the stock is trading at USD 9.50 with a total of 161,337 shares traded.
Over the past week, the price has changed by -5.00%, over one month by -9.61%, over three months by -2.56% and over the past year by -3.65%.
Is Veradigm a good stock to buy?
Neither. Based on ValueRay Analyses, Veradigm is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 3.70 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MDRX as of December 2024 is 8.62. This means that MDRX is currently overvalued and has a potential downside of -9.26%.
Neither. Based on ValueRay Analyses, Veradigm is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 3.70 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MDRX as of December 2024 is 8.62. This means that MDRX is currently overvalued and has a potential downside of -9.26%.
Is MDRX a buy, sell or hold?
Veradigm has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold MDRX.
Veradigm has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold MDRX.
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecast for MDRX stock price target?
According to ValueRays Forecast Model, MDRX Veradigm will be worth about 9.5 in December 2025. The stock is currently trading at 9.50. This means that the stock has a potential downside of -0.42%.
According to ValueRays Forecast Model, MDRX Veradigm will be worth about 9.5 in December 2025. The stock is currently trading at 9.50. This means that the stock has a potential downside of -0.42%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 12.8 | 34.2% |
Analysts Target Price | 17.5 | 84.2% |
ValueRay Target Price | 9.5 | -0.4% |